{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T22:06:30Z","timestamp":1762639590747,"version":"build-2065373602"},"reference-count":37,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T00:00:00Z","timestamp":1751241600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2025,10]]},"DOI":"10.1016\/j.jtct.2025.06.019","type":"journal-article","created":{"date-parts":[[2025,6,24]],"date-time":"2025-06-24T11:12:49Z","timestamp":1750763569000},"page":"820.e1-820.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["High-Dose Melphalan Followed by Busulfan and Fludarabine Conditioning Prior to Allogeneic Stem Cell Transplantation in Elderly Patients with Active Acute Myeloid Leukemia\u2014A Retrospective Single-Center Study"],"prefix":"10.1016","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-1955-0709","authenticated-orcid":false,"given":"Julian","family":"Ronnacker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-1019-5150","authenticated-orcid":false,"given":"Marc-Andre","family":"Urbahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Reicherts","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Simon","family":"Call","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva","family":"E\u00dfeling","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-0916-070X","authenticated-orcid":false,"given":"Mathias","family":"Floeth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Marx","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J\u00f6rn","family":"Albring","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan-Henrik","family":"Mikesch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1755-9583","authenticated-orcid":false,"given":"Christoph","family":"Schliemann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg","family":"Lenz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9331-5145","authenticated-orcid":false,"given":"Matthias","family":"Stelljes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.jtct.2025.06.019_bib0001","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1111\/bjh.19552","article-title":"Early blast clearance during sequential conditioning prior to allogeneic stem cell transplantation in patients with acute myeloid leukaemia","volume":"205","author":"Ronnacker","year":"2024","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2025.06.019_bib0002","doi-asserted-by":"crossref","first-page":"547","DOI":"10.2147\/CMAR.S339846","article-title":"Allogeneic stem cell transplantation with sequential melphalan-based conditioning in AML: residual morphological blast count determines the risk of relapse","volume":"14","author":"Sockel","year":"2022","journal-title":"Cancer Manag Res"},{"issue":"7","key":"10.1016\/j.jtct.2025.06.019_bib0003","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/bmt.2016.325","article-title":"Factors predicting outcome after allogeneic transplant in refractory acute myeloid leukemia: a retrospective analysis of Gruppo Italiano Trapianto di Midollo Osseo (GITMO)","volume":"52","author":"Todisco","year":"2017","journal-title":"Bone Marrow Transplant"},{"issue":"25","key":"10.1016\/j.jtct.2025.06.019_bib0004","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1200\/JCO.20.03736","article-title":"Venetoclax combined with FLAG-IDA induction and consolidation in newly diagnosed and relapsed or refractory acute myeloid leukemia","volume":"39","author":"DiNardo","year":"2021","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2025.06.019_bib0005","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1182\/blood-2023-184445","article-title":"Venetoclax plus high-dose cytarabine and mitoxantrone (HAM-Ven) as salvage treatment for relapsed\/refractory AML: updated results of the phase-I\/II SAL relax trial","volume":"142","author":"Ruhnke","year":"2023","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.jtct.2025.06.019_bib0006","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1182\/bloodadvances.2024013086","article-title":"Venetoclax-based salvage therapy as bridge-to-transplant is feasible and effective in patients with relapsed\/refractory AML","volume":"9","author":"Unglaub","year":"2025","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"10.1016\/j.jtct.2025.06.019_bib0007","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1182\/blood-2023-185956","article-title":"MRD directed treatment intensification with either FLAG-Ida or DA-cladribine improves survival in older AML patients: results from the NCRI AML18 randomised trial","volume":"142","author":"Russell","year":"2023","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.jtct.2025.06.019_bib0008","doi-asserted-by":"crossref","first-page":"e324","DOI":"10.1016\/S2352-3026(24)00065-6","article-title":"Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial","volume":"11","author":"Stelljes","year":"2024","journal-title":"Lancet Haematol"},{"issue":"13","key":"10.1016\/j.jtct.2025.06.019_bib0009","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1200\/JCO.23.01911","article-title":"Azacitidine, venetoclax, and gilteritinib in newly diagnosed and relapsed or refractory FLT3-mutated AML","volume":"42","author":"Short","year":"2024","journal-title":"J Clin Oncol"},{"issue":"24","key":"10.1016\/j.jtct.2025.06.019_bib0010","doi-asserted-by":"crossref","first-page":"5675","DOI":"10.1200\/JCO.2005.07.061","article-title":"Sequential regimen of chemotherapy, reduced-intensity conditioning for allogeneic stem-cell transplantation, and prophylactic donor lymphocyte transfusion in high-risk acute myeloid leukemia and myelodysplastic syndrome","volume":"23","author":"Schmid","year":"2005","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jtct.2025.06.019_bib0011","doi-asserted-by":"crossref","first-page":"1092","DOI":"10.1182\/blood-2005-10-4165","article-title":"Long-term survival in refractory acute myeloid leukemia after sequential treatment with chemotherapy and reduced-intensity conditioning for allogeneic stem cell transplantation","volume":"108","author":"Schmid","year":"2006","journal-title":"Blood"},{"issue":"12","key":"10.1016\/j.jtct.2025.06.019_bib0012","doi-asserted-by":"crossref","first-page":"1524","DOI":"10.1002\/ajh.25281","article-title":"Sequential HLA-haploidentical transplantation utilizing post-transplantation cyclophosphamide for GvHD prophylaxis in high-risk and relapsed\/refractory AML\/MDS","volume":"93","author":"Fraccaroli","year":"2018","journal-title":"Am J Hematol"},{"issue":"6","key":"10.1016\/j.jtct.2025.06.019_bib0013","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/bjh.15137","article-title":"High-dose melphalan-based sequential conditioning chemotherapy followed by allogeneic haematopoietic stem cell transplantation in adult patients with relapsed or refractory acute myeloid leukaemia","volume":"180","author":"Steckel","year":"2018","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.jtct.2025.06.019_bib0014","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/10428194.2020.1827248","article-title":"Evaluation of six different types of sequential conditioning regimens for allogeneic stem cell transplantation in relapsed\/refractory acute myelogenous leukemia\u2014a study of the acute leukemia working party of the EBMT","volume":"62","author":"Heinicke","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"10.1016\/j.jtct.2025.06.019_bib0015","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00277-016-2887-4","article-title":"Similar outcome after allogeneic stem cell transplantation with a modified FLAMSA conditioning protocol substituting 4 Gy TBI with treosulfan in an elderly population with high-risk AML","volume":"96","author":"Holtick","year":"2017","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.jtct.2025.06.019_bib0016","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s00277-011-1253-9","article-title":"Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemia","volume":"91","author":"Chemnitz","year":"2012","journal-title":"Ann Hematol"},{"issue":"9","key":"10.1016\/j.jtct.2025.06.019_bib0017","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1007\/s00277-020-04131-1","article-title":"The FLAMSA concept-past and future","volume":"99","author":"Kolb","year":"2020","journal-title":"Ann Hematol"},{"issue":"2","key":"10.1016\/j.jtct.2025.06.019_bib0018","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.bbmt.2016.11.002","volume":"23","author":"Malard","year":"2017","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"10.1016\/j.jtct.2025.06.019_bib0019","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/j.bbmt.2007.08.047","article-title":"A scheme for defining cause of death and its application in the T cell depletion trial","volume":"13","author":"Copelan","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"10.1016\/j.jtct.2025.06.019_bib0020","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.bbmt.2015.09.001","article-title":"International, multicenter standardization of acute graft-versus-host disease clinical data collection: a report from the Mount Sinai acute GVHD international consortium","volume":"22","author":"Harris","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"issue":"3","key":"10.1016\/j.jtct.2025.06.019_bib0021","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/j.bbmt.2014.12.001","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. The 2014 Diagnosis and Staging Working Group report","volume":"21","author":"Jagasia","year":"2015","journal-title":"Biol Blood Marrow Transplant"},{"issue":"4","key":"10.1016\/j.jtct.2025.06.019_bib0022","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.jtct.2025.06.019_bib0023","doi-asserted-by":"crossref","first-page":"2912","DOI":"10.1182\/blood-2005-05-2004","article-title":"Hematopoietic cell transplantation (HCT)-specific comorbidity index: a new tool for risk assessment before allogeneic HCT","volume":"106","author":"Sorror","year":"2005","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jtct.2025.06.019_bib0024","doi-asserted-by":"crossref","first-page":"e572","DOI":"10.1097\/HS9.0000000000000572","article-title":"Treatment for relapsed\/refractory acute myeloid leukemia","volume":"5","author":"Thol","year":"2021","journal-title":"HemaSphere"},{"issue":"1","key":"10.1016\/j.jtct.2025.06.019_bib0025","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1182\/blood.2023022481","article-title":"How I treat refractory and relapsed acute myeloid leukemia","volume":"143","author":"Thol","year":"2024","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.jtct.2025.06.019_bib0026","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1182\/blood.2021015129","article-title":"How I prevent GVHD in high-risk patients: posttransplant cyclophosphamide and beyond","volume":"141","author":"Rimando","year":"2023","journal-title":"Blood"},{"issue":"19","key":"10.1016\/j.jtct.2025.06.019_bib0027","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease","volume":"382","author":"Zeiser","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jtct.2025.06.019_bib0028","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1056\/NEJMoa2033122","article-title":"Ruxolitinib for glucocorticoid-refractory chronic graft-versus-host disease","volume":"385","author":"Zeiser","year":"2021","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.jtct.2025.06.019_bib0029","doi-asserted-by":"crossref","DOI":"10.3390\/cancers16030532","article-title":"Smart conditioning with venetoclax-enhanced sequential FLAMSA + RIC in patients with high-risk myeloid malignancies","volume":"16","author":"Schulz","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"5","key":"10.1016\/j.jtct.2025.06.019_bib0030","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1080\/14712598.2022.2060735","article-title":"Where do we stand with radioimmunotherapy for acute myeloid leukemia?","volume":"22","author":"Walter","year":"2022","journal-title":"Expert Opin Biol Ther"},{"issue":"10","key":"10.1016\/j.jtct.2025.06.019_bib0031","doi-asserted-by":"crossref","first-page":"1376","DOI":"10.1038\/s41409-024-02319-x","article-title":"Longitudinal outcome over four decades of allogeneic stem cell transplantation: a single center experience","volume":"59","author":"Sanz","year":"2024","journal-title":"Bone Marrow Transplant"},{"issue":"28","key":"10.1016\/j.jtct.2025.06.019_bib0032","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1200\/JCO.24.00582","article-title":"Human leukocyte antigen mismatching and survival in contemporary hematopoietic cell transplantation for hematologic malignancies","volume":"42","author":"Arrieta-Bola\u00f1os","year":"2024","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.jtct.2025.06.019_bib0033","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1182\/blood.2021011975","article-title":"HLA still matters in allogeneic transplants","volume":"138","author":"Bacigalupo","year":"2021","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jtct.2025.06.019_bib0034","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1182\/blood.2021011281","article-title":"HLA-haploidentical vs matched unrelated donor transplants with posttransplant cyclophosphamide-based prophylaxis","volume":"138","author":"Gooptu","year":"2021","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jtct.2025.06.019_bib0035","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1038\/leu.2017.23","article-title":"Impact of salvage regimens on response and overall survival in acute myeloid leukemia with induction failure","volume":"31","author":"Wattad","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2025.06.019_bib0036","article-title":"Venetoclax combined chemotherapy versus chemotherapy alone for acute myeloid leukemia: a systematic review and meta-analysis","volume":"14","author":"Zhu","year":"2024","journal-title":"Front Oncol"},{"key":"10.1016\/j.jtct.2025.06.019_bib0037","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1111\/bjh.18229","article-title":"Hypomethylating agent\/venetoclax versus intensive chemotherapy in adults with relapsed or refractory acute myeloid leukaemia","volume":"198","author":"Jamy","year":"2022","journal-title":"Br J Haematol"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725012631?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636725012631?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T22:02:08Z","timestamp":1762639328000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636725012631"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10]]},"references-count":37,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["S2666636725012631"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2025.06.019","relation":{},"ISSN":["2666-6367"],"issn-type":[{"type":"print","value":"2666-6367"}],"subject":[],"published":{"date-parts":[[2025,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"High-Dose Melphalan Followed by Busulfan and Fludarabine Conditioning Prior to Allogeneic Stem Cell Transplantation in Elderly Patients with Active Acute Myeloid Leukemia\u2014A Retrospective Single-Center Study","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2025.06.019","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Inc. on behalf of The American Society for Transplantation and Cellular Therapy.","name":"copyright","label":"Copyright"}]}}